Funding Round For Cambridge Biotech Company Completed
News Nov 14, 2005
Activotec has announced that it has just completed a significant funding round to enable it to accelerate the growth of the company.
The money was raised quickly through a syndicate mainly composed of private high net worth investors, was significantly oversubscribed and had to be scaled back.
Activotec chief executive, Chris Littlewood, commented, "The funds will be invested in further research and development while expanding our current business."
"This will assist us in our dual strategy of creating and licensing technology to drug developers while also quickly growing our custom peptide and synthesiser sales."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE